Glenmark Pharmaceuticals South Africa (Glenmark) has announced the expansion of its topical dermatology portfolio with signing a 10 year marketing and distribution rights agreement with MeyerZall Laboratories.

Therapeutic areas covered by this distribution agreement include Psoriasis, Fungal infections of the skin and inflammation with the following products now falling into the Glenmark portfolio; Linotar Gel 1, Covarex and Athru-Derm, all with unique patented delivery systems which are available for distribution through PHD.

AS Mohanty, director - formulations, Glenmark Pharmaceuticals Ltd, said, "With the addition of these products to Glenmark's portfolio, we are now able to offer one of the widest topical dermatology baskets in the South African market. This will significantly add to our existing range of Synalar, Synalar-C, Synalar-N and Naseptin, and create a significant niche in the area of dermatology for Glenmark in South Africa".

In December 2005, Glenmark Pharmaceuticals Ltd had acquired Bouwer Bartlett Pty Ltd., a South African sales and marketing company, through its wholly owned Swiss subsidiary. Currently, its pharmaceutical business unit produces, markets, sells and distributes a range of ethical dermatological products including brands like Synalar and Naseptin.

Glenmark is one of the leading players in the Indian dermatology segment with Candid B featuring among the top 300 pharmaceutical products in the country.